Daiwa Securities Group
ADAP

Daiwa Securities Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Daiwa Securities Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-469
Closed – – 1321
2023
Q3 		$0 Hold
469
– – ﹤0.01% 1288
2023
Q2 		$0 Hold
469
– – ﹤0.01% 1318
2023
Q1 		$1K Hold
469
– – ﹤0.01% 1237
2022
Q4 		$1K Hold
469
– – ﹤0.01% 1254
2022
Q3 		$1K Sell
469
-18,409
-98% -$33.8K ﹤0.01% 1263
2022
Q2 		$32K Sell
18,878
-16,638
-47% -$28.6K ﹤0.01% 1100
2022
Q1 		$73K Buy
35,516
+11,001
+45% +$29.7K ﹤0.01% 1071
2021
Q4 		$92K Buy
24,515
+9,133
+59% +$41.6K ﹤0.01% 1019
2021
Q3 		$80K Buy
15,382
+15,126
+5,909% +$67.9K ﹤0.01% 1010
2021
Q2 		$1K Hold
256
– – ﹤0.01% 1174
2021
Q1 		$1K Hold
256
– – ﹤0.01% 1180
2020
Q4 		$1K Buy
+256
New +$1.39K ﹤0.01% 1157
2019
Q4 		– Sell
-323
Closed – – 1200
2019
Q3 		$0 Hold
323
– – ﹤0.01% 1178
2019
Q2 		$1K Hold
323
– – ﹤0.01% 1169
2019
Q1 		$1K Hold
323
– – ﹤0.01% 1157
2018
Q4 		$2K Hold
323
– – ﹤0.01% 1101
2018
Q3 		$4K Hold
323
– – ﹤0.01% 1088
2018
Q2 		$4K Hold
323
– – ﹤0.01% 1103
2018
Q1 		$4K Buy
+323
New +$2.83K ﹤0.01% 1084

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Daiwa Securities Group's ADAP Position: Q4 2023 in Review

Daiwa Securities Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 469 shares.

Daiwa Securities Group first reported a position in ADAP in Q1 2018 and held it in 19 quarters. The position peaked at $92K in Q4 2021. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • Daiwa Securities Group reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 469 Adaptimmune Therapeutics shares in Q4 2023.
  • Daiwa Securities Group first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 19 quarters.
  • Daiwa Securities Group's Adaptimmune Therapeutics position peaked at $92K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.